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Pulse pressure is a well established marker of vascular
stiffness and is associated with increased mortality in
hemodialysis patients. Here we sought to determine if a
decrease in pulse pressure during hemodialysis was
associated with improved outcomes using data from 438
hemodialysis patients enrolled in the 6-month Crit-Line
Intradialytic Monitoring Benefit Study. The relationship
between changes in pulse pressure during dialysis (2-week
average) and the primary end point of non-access-related
hospitalization and death were adjusted for demographics,
comorbidities, medications, and laboratory variables. In the
analyses that included both pre- and post-dialysis pulse
pressure, higher pre-dialysis and lower post-dialysis pulse
pressure were associated with a decreased hazard of the
primary end point. Further, every 10mmHg decrease in pulse
pressure during dialysis was associated with a 20% lower
hazard of the primary end point. In separate models that
included pulse pressure and the change in pulse pressure
during dialysis, neither pre- nor post-dialysis pulse pressure
were associated with the primary end point, but each
10mmHg decrease in pulse pressure during dialysis was
associated with about a 20% lower hazard of the primary end
point. Our study found that in prevalent dialysis subjects, a
decrease in pulse pressure during dialysis was associated
with improved outcomes. Further study is needed to identify
how to control pulse pressure to improve outcomes.
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Despite significantly elevated cardiovascular morbidity and
mortality in hemodialysis patients,1 the appropriate blood
pressure target to optimize clinical outcomes in dialysis
patients remains to be determined.2 In the general popula-
tion, elevated pulse pressure, as a marker of conduit vessel
stiffness, is clearly associated with adverse cardiovascular
outcomes.3–5 Further, lowering pulse pressure in hypertensive
patients is associated with improved cardiovascular out-
comes.6 In hemodialysis patients, prior analyses demonstrate
elevated pre- and post-dialysis pulse pressure to be important
predictors of all-cause mortality.7,8 However, the optimal
control of pulse pressure to improve outcomes in hemodia-
lysis patients remains to be determined.
Abnormalities of the arterial system are common in
dialysis patients and are associated with increased cardiovas-
cular morbidity and mortality.9 The increased mortality
associated with increased arterial stiffness (caused by
increasing age, hypertension, uremia, and abnormalities in
mineral metabolism) is likely the result of the increased
systolic stress, which increases left ventricular afterload,
decreases coronary perfusion, and leads to left ventricular
hypertrophy. Non-invasive measurements of arterial stiffness
include pulse wave velocity and pulse pressure (the difference
between systolic and diastolic blood pressure). Whereas both
increased pulse wave velocity and increased pulse pressure are
associated with higher mortality in hemodialysis pa-
tients,7,8,10 only reductions in pulse wave velocity have been
demonstrated to be associated with regression of left
ventricular hypertrophy and improved survival.11,12 This
raises the possibility that a decrease in pulse pressure during
hemodialysis sessions may be a marker of improved vascular
health. We hypothesized that a decrease in pulse pressure
during hemodialysis is associated with improved clinical
outcomes. To test this hypothesis, we analyzed data from
prevalent hemodialysis subjects enrolled in a randomized
controlled trial of blood volume monitoring.
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RESULTS
Baseline characteristics
In the entire cohort, the mean pre- and post-dialysis pulse
pressures were 70 and 64mmHg, respectively. Subjects with
greater reductions in pulse pressure during hemodialysis had
higher dry weights, larger interdialytic weight gains, and
trends toward higher prevalence of left ventricular hyper-
trophy (Table 1). Subjects with greater reductions in pulse
pressure during hemodialysis also exhibited higher pre-
dialysis systolic blood pressure and lower post-dialysis
systolic blood pressure but no significant difference in pre-
or post-dialysis diastolic blood pressure (Figure 1). While
there were no significant differences in most laboratory
variables or antihypertensive class agent use between subjects
categorized by quartiles of pulse pressure change with
hemodialysis, subjects with greater reductions in pulse
pressure with hemodialysis exhibited higher serum calcium.
Event rates across quartiles of pulse pressure change during
hemodialysis
Overall, there were 24 deaths during the 6-month follow-up
and 127 subjects were hospitalized for a non-access-related
complication (Table 2). Subjects whose pulse pressure
decreased413.8mmHg during hemodialysis had the lowest
event rates during follow-up, including the combined end
point of time to non-access-related hospitalization or death,
annual non-access related hospitalization rates, as well as
all-cause mortality (Table 2).
Unadjusted analysis of hospitalization or death at 6 months
In unadjusted analyses, a decrease in pulse pressure during
hemodialysis (per 10mmHg) was associated with a 24%
decreased hazard ratio (HR) of hospitalization or death (HR
0.76, confidence interval (CI) 0.65–0.88, P¼ 0.0002; Table 3).
In unadjusted univariate analyses, higher pre-dialysis pulse
pressure was not associated with increased HR of the primary
end point, whereas higher post-dialysis pulse pressure (per
10mmHg) was associated with a 13% increased hazard of
death or hospitalization (Table 3). However, in models
including both pre- and post-dialysis pulse pressure, lower
pre-dialysis pulse pressure and higher post-dialysis pulse
pressure were associated with increased hazard of hospitali-
zation or death. Interestingly, in models including either pre-
or post-dialysis pulse pressure and change in pulse pressure
during dialysis, neither pre- nor post-dialysis pulse pressure
remained associated with the primary end point, whereas a
decrease in pulse pressure during hemodialysis was associated
with an B24% reduced hazard of death or hospitalization
(Table 3).
Adjusted analyses of hospitalization or death at 6 months
In fully adjusted models, neither pre- nor post-dialysis pulse
pressure tested individually was significantly associated with
the primary end point (Table 3 and Figure 2). However, when
tested together, lower pre-dialysis pulse pressure and higher
post-dialysis pulse pressure were associated with increased
hazard of the primary end point. In models including either
pre- or post-dialysis pulse pressure and change in pulse
pressure during hemodialysis, neither pre- nor post-dialysis
pulse pressure were associated with the primary end point,
whereas a decrease of pulse pressure during hemodialysis was
associated with anB20% reduction in the primary end point
of death or hospitalization at 6 months (adjusted HR 0.81, CI
0.69–0.97 for pulse pressure decreasing with hemodialysis
adjusted for pre-dialysis pulse pressure; HR 0.79, CI 0.65–0.94
for decreasing pulse pressure with hemodialysis adjusted for
post-dialysis pulse pressure).
In the final multivariable model adjusted for age, gender,
race, comorbidity, and relevant laboratory variables, a
decrease of pulse pressure during hemodialysis (per
10mmHg) was significantly associated with a 20% reduced
hazard of the primary end point (HR 0.80, CI 0.69–0.94,
P¼ 0.007; Table 4). Variables associated with increased
hazard of the primary end point included history of tobacco
use and presence of cerebrovascular disease, coronary
artery disease, and congestive heart failure. Higher hemo-
globin and higher dry weights were associated with
decreased hazard of the primary end point. When Dpulse
pressure was analyzed as a time-varying covariate in fully
adjusted models, there was a 13% reduced hazard of
the primary end point associated with every 10mmHg
decrease in pulse pressure during hemodialysis (HR 0.87,
CI 0.80–0.95, P¼ 0.002).
Dialysis-related events and pulse pressure changes during
follow-up
Considering we identified differences in outcomes across
groups of subjects based on pulse pressure responses to
hemodialysis, we explored the subsequent occurrence of
dialysis-related complications among subjects during the
6-month follow-up (Table 5). In general, subjects whose
pulse pressure decreased during dialysis had greater
frequency of intradialytic hypotension. There was also a
trend toward greater use of intradialytic medications among
subjects whose pulse pressure decreased with hemodialysis.
Interestingly, there was no difference across subjects with
regards to symptomatic complaints of cramping, dizziness, or
nausea/vomiting. While rates of treatment sessions using
hypertonic saline or sodium modeling was higher among
subjects whose pulse pressure decreased during hemodialysis,
use of cool dialysate was lowest among these subjects.
During the 6-month follow-up, regression to the mean
occurred for the monthly mean change in pulse pressure
during hemodialysis among subjects whose pulse pressure
increased during hemodialysis (quartile 4; Figure 3) or whose
pulse pressure decreased during hemodialysis (quartile 1;
Figure 3). Despite this, subjects generally demonstrated
similar pulse pressure responses to hemodialysis at month
6 as they did at baseline. For example, subjects in quartile 1
consistently demonstrated 410-mmHg decreases in pulse
pressure during hemodialysis throughout the 6-month
follow-up period.
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Sensitivity analyses
Since pre-dialysis systolic blood pressure is an important
determinant of clinical outcomes, pre-dialysis systolic blood
pressure was added to the final model to determine if it
modified the relationship between decrease in pulse pressure
during hemodialysis and clinical outcomes. In models adjusted
for systolic blood pressure, there continued to be lower hazard
of death or hospitalization associated with decrease of pulse
pressure during hemodialysis (HR 0.81, CI 0.68–0.96, P¼ 0.01)
A separate model analyzing the association between
decrease in pulse pressure during hemodialysis and the
primary combined end point across strata of pre-dialysis
systolic blood pressure was designed. Figure 4 demonstrates
that the association between decrease in pulse pressure
during hemodialysis and lower hazard of the primary end
point persisted across subjects whose pre-dialysis systolic
blood pressure values were X120mmHg, which represents
93% of the cohort. As expected, subjects whose pre-dialysis
Table 1 | Baseline clinical and demographic characteristics of the study population across quartiles of pulse pressure change
during hemodialysis
Quartile 1 (Dpulse
pressure
o13.8mmHg, n¼ 111)
Quartile 2 (Dpulse pressure
X13.8mmHg,
o5.4mmHg, n¼ 108)
Quartile 3 (Dpulse
pressureX5.4mmHg,
o2.6mmHg, n¼ 108)
Quartile 4 (Dpulse
pressure X2.6mmHg,
n¼ 111) P-value*
Age (years) 59.7 (±13.8) 57.9 (±15.4) 56.2 (±17.1) 62.9 (±15.5) 0.01
Gender (% male) 54.1% 52.8% 52.8% 45.1% 0.5
Black race (%) 41.4% 34.3% 32.4% 31.5% 0.5
Dialysis vintage (years)a 2.2 (0.42–7.7) 2.3 (0.32–13.5) 1.64 (0.29–10.3) 2.0 (0.34–8.0) 0.13
Dry weight (kg) 82.3 (±25.1) 76.7 (±18.2) 76.0 (±21.7) 73.4 (±17.0) 0.009
% IDWL 4.09 (±1.16) 3.83 (±1.21) 4.04 (±1.39) 3.60 (±1.29) 0.01
Tobacco use 31.5% 23.2% 38.9% 27.9% 0.08
Diabetes (cause of ESRD) 37.8% 23.2% 27.8% 33.3% 0.10
Hypertension 92.8% 86.1% 86.1% 87.4% 0.4
Arrhythmia 21.6% 16.7% 13.0% 19.8% 0.4
Coronary artery disease 27.0% 32.4% 24.6% 34.2% 0.4
Congestive heart failure 21.6% 25.9% 19.4% 16.2% 0.4
Cerebrovascular disease 25.2% 14.8% 16.7% 16.2% 0.2
Left ventricular hypertrophy 46.9% 48.2% 38.0% 31.5% 0.04
Peripheral vascular disease 21.1% 19.4% 21.8% 16.2% 0.7
Pre-dialysis BP (mmHg)
Pulse pressure 79.5 (±13.4) 68.8 (±12.1) 65.1 (±13.1) 66.5 (±15.5) o0.0001
Systolic 160.9 (±16.0) 148.5 (±18.1) 144.6 (±18.8) 144.4 (22.9) o0.0001
Diastolic 81.3 (±11.0) 79.6 (±11.7) 79.5 (±13.1) 77.9 (±13.7) 0.2
Post-dialysis BP (mmHg)
Pulse pressure 59.0 (±11.3) 59.0 (±12.2) 63.5 (±13.5) 75.2 (±16.0) o0.0001
Systolic 130.7 (±14.8) 132.1 (±17.7) 137.8 (±18.9) 150.7 (±21.1) o0.0001
Diastolic 71.8 (±10.1) 73.1 (±11.7) 74.3 (±11.7) 75.5 (±11.5) 0.09
DPulse pressure (mmHg) 20.5 (±7.3) 9.9 (±2.1) 1.6 (±2.2) 8.8 (±5.9) o0.0001
Baseline laboratorya
Albumin (g/dl) 3.71 (±0.34) 3.79 (±0.62) 3.73 (±0.56) 3.74 (±0.40) 0.7
Creatinine (mg/dl) 9.6 (±3.0) 9.6 (±2.9) 9.1 (±3.5) 8.7 (±2.9) 0.08
Calcium (mg/dl) 9.4 (±0.98) 9.3 (±0.98) 9.0 (±0.88) 9.1 (±0.78) 0.006
Phosphorus (mg/dl) 5.6 (±1.8) 6.0 (±1.9) 5.8 (±2.0) 5.4 (±1.7) 0.1
Hemoglobin (g/dl) 11.3 (±1.2) 11.6 (±1.4) 11.6 (±1.4) 11.2 (±1.3) 0.05
Urea reduction ratio 0.71 (±0.07) 0.72 (±0.07) 0.71 (±0.09) 0.70 (±0.31) 0.9
Number of antihypertensive
medications
1.44 (±1.14) 1.46 (±1.10) 1.29 (±1.17) 1.67 (±1.08) 0.09
Antihypertensive class
ACE-I 34.2% 28.7% 23.2% 33.3% 0.3
a-Blocker 5.4% 5.6% 5.6% 2.7% 0.7
b-Blocker 30.6% 38.9% 31.5% 36.9% 0.5
Calcium channel blk 42.3% 37.0% 32.4% 44.1% 0.3
Nitrate 10.8% 15.7% 13.0% 21.6% 0.1
Vasodilator 17.4% 12.0% 19.1% 25.2% 0.09
Epoetin use 88.3% 88.0% 89.8% 91.9% 0.8
Treatment group (versus
usual care)
50.5% 53.7% 48.2% 41.4% 0.3
ACE-I, angiotensin-converting enzyme inhibitor; channel blk, channel blocker; BP, blood pressure; ESRD, end-stage renal disease; IDWL, intradialytic weight loss.
Data presented as mean (s.d.) or median (interquartile range).
*w2 analysis was used for categorical P-values and analysis of variance or Kruskal–Wallis was used for continuous P-values.
IDWL¼ (pre-dialysis weightpost-dialysis weight/target dry weight) 100.
aDialysis vintage is missing for 9 subjects and urea reduction ratio for 44 subjects.
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systolic blood pressure was low (o120mmHg) exhibited a
trend toward worse outcomes associated with a decrease in
pulse pressure during hemodialysis.
Finally, we analyzed whether the relationship between
decrease in pulse pressure and lower hazard of the primary
end point was modified by the amount of intradialytic weight
loss or use of specific antihypertensive agents. There was no
interaction between intradialytic weight loss and decrease in
pulse pressure during hemodialysis (P¼ 0.3) as a predictor of
the primary end point. Further, the relationship between
decreased pulse pressure during hemodialysis and lower
hazard of the primary end point persisted across all strata of
intradialytic weight loss (data not shown). In the initial
models, including the entire cohort of subjects, no specific
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Figure 1 |Average pre- and post-dialysis systolic blood pressure (SBP) and diastolic blood pressure (DBP) among subjects grouped
by quartiles of pulse pressure (PP) change during dialysis. HD, hemodialysis.
Table 2 | Outcomes among subjects grouped by quartiles of pulse pressure change during hemodialysis
Quartile 1 (Dpulse
pressure o13.8mmHg,
n¼ 111)
Quartile 2 (Dpulse
pressure X13.8,
o5.4mmHg, n¼ 108)
Quartile 3 (Dpulse
pressure X5.4,
o2.6mmHg, n¼ 108)
Quartile 4 (Dpulse
pressure X2.6mmHg,
n¼ 111)
Hazard ratio of the primary end point of
non-access-related hospitalization or death
1.00 (ref) 2.01 (1.14–3.54) 2.46 (1.42–4.23) 2.35 (1.36–4.06)
Annual non-access-related hospitalization ratesa 0.50 0.93 1.30 1.16
Six-month all-cause mortality (n) (%) 3 (2.7%) 7 (6.5%) 8 (7.4%) 6 (5.4%)
ref, reference.
aMay include more than one hospitalization per subject.
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blood pressure medications were associated with the primary
end point (data not shown). Overall, 76% (333/438) of the
cohort was treated with antihypertensive medications, but
none of the blood pressure medications were associated with
the primary end point nor did their use modify the primary
results (data not shown).
DISCUSSION
The principal new finding in this study is that a decrease in
pulse pressure during hemodialysis is associated with better
short-term outcomes in prevalent hemodialysis subjects.
Furthermore, our investigation demonstrated that despite
higher rates of intradialytic hypotension, decrease in pulse
pressure during hemodialysis was more strongly associated
with improved clinical outcomes than pre- or post-dialysis
pulse pressure either alone or combined. Finally, while this
study was not targeted toward lowering pulse pressure
with hemodialysis, the observation that subjects whose
pulse pressure decreased during hemodialysis had better
outcomes suggests blood pressure responses to hemodialysis
may be an important risk factor which warrants further
investigations.
Prior investigations in hemodialysis patients have identi-
fied elevated pre- and post-dialysis pulse pressure to be
associated with higher mortality.7,8 In an investigation of
37,069 prevalent hemodialysis patients, every 10-mmHg
increase in post-dialysis pulse pressure was associated with a
12% increased hazard of death at 1 year. Similarly, this study
identified every 10-mmHg increase in post-dialysis pulse
pressure (when adjusted for pre-dialysis pulse pressure) to be
associated with a 22% increased hazard of death or
hospitalization. Interestingly, the relationship between ele-
vated post-dialysis pulse pressure and adverse outcomes was
minimized when decreasing pulse pressure during hemodia-
lysis was added to the model; thus suggesting that decrease in
Table 3 | Unadjusted and adjusted hazard of hospitalization or death associated with pre-dialysis pulse pressure (PP),
post-dialysis PP, change in pulse pressure during hemodialysis, or a combination of pulse pressure measurements
Model Blood pressure variable (per 10mmHg)
Unadjusted HR
(95% CI) P-value
Adjusteda HR
(95% CI) P-value
1 Pre-dialysis pulse pressure (per 10-mmHg increase) 0.94 (0.84–1.06) 0.3 0.91 (0.79–1.04) 0.2
2 Post-dialysis pulse pressure (per 10-mmHg increase) 1.13 (1.01–1.27) 0.04 1.06 (0.93–1.21) 0.4
3 Change in pulse pressure during hemodialysis (per 10-mmHg decrease) 0.76 (0.65–0.88) 0.0002 0.80 (0.69–0.94) 0.007
4 Pre-dialysis pulse pressure (per 10-mmHg increase) 0.77 (0.65–0.91) 0.002 0.79 (0.66–0.95) 0.01
Post-dialysis pulse pressure (per 10-mmHg increase) 1.33 (1.14–1.55) 0.0003 1.22 (1.03–1.45) 0.02
5 Pre-dialysis pulse pressure (per 10-mmHg increase) 1.03 (0.90–1.17) 0.69 0.97 (0.83–1.12) 0.6
Change in pulse pressure during hemodialysis (per 10-mmHg decrease) 0.75 (0.64–0.87) 0.0002 0.81 (0.69–0.97) 0.02
6 Post-dialysis pulse pressure (per 10-mmHg increase) 1.03 (0.90–1.17) 0.71 0.96 (0.83–1.12) 0.6
Change in pulse pressure during hemodialysis (per 10-mmHg decrease) 0.77 (0.65–0.91) 0.002 0.79 (0.65–0.94) 0.01
CI, confidence interval; HR, hazard ratio; PP, pulse pressure.
aEach model is adjusted for age, race, gender, dry weight, intradialytic weight loss, tobacco use, diabetes, cerebrovascular disease, coronary artery disease, congestive heart
disease, presence of left ventricular hypertrophy, hypoalbuminemia, serum calcium, phosphorus, hemoglobin, nitrate, and treatment arm.
Adjusted HR (95% Cl) for hospitalization or death associated
with pre-HD PP, post-HD PP, and a decrease in PP during HD
1.5
1
0.5
Ad
jus
ted
 ha
za
rd 
rat
io
s 
(pe
r 1
0 m
m 
Hg
)
0.91
1.06
0.8 0.79
1.22
0.97
0.81
0.96
0.79
Pre
-HD
 
PP
Po
st-
HD
 PP
Pre
-HD
 
PP
Po
st-
HD
 PP
Pre
-HD
 
PP
Po
st-
HD
 PP
De
cre
ase
 in 
PP
De
cre
ase
 in 
PP
De
cre
ase
 in 
PP
Alone 2 Together 2 Together 2 Together
Figure 2 |Adjusted* hazard ratio for hospitalization or death
associated with the following blood pressure parameters
analyzed in six separate models. (1) Pre-dialysis pulse pressure
modeled individually. (2) Post-dialysis pulse pressure modeled
individually. (3) Change in pulse pressure during hemodialysis
modeled individually. (4) Pre-dialysis pulse pressure and
post-dialysis pulse pressure modeled together. (5) Pre-dialysis
pulse pressure and change in pulse pressure during hemodialysis
modeled together. (6) Post-dialysis pulse pressure and change
in pulse pressure during hemodialysis modeled together. *In
addition to the listed blood pressure parameter(s), each model is
adjusted for age, race, gender, dry weight, intradialytic weight
loss, tobacco use, diabetes, cerebrovascular disease, coronary
artery disease, congestive heart failure, presence of left ventricular
hypertrophy, hypoalbuminemia, serum calcium, phosphorus,
hemoglobin, nitrate, and treatment arm. CI, confidence interval;
HD, hemodialysis; HR, hazard ratio; PP, pulse pressure.
Table 4 | Cox proportional hazards model of time to
hospitalization or death among end-stage renal disease
subjects
Variable HR (95% CI) P-value
Change in pulse pressure during
hemodialysis (per 10-mmHg decrease)
0.80 (0.69–0.94) 0.007
Dry weight (per 1-kg increase) 0.98 (0.98–1.00) 0.02
Tobacco use 1.51 (1.01–2.26) 0.04
Cerebrovascular disease 1.51 (1.13–1.71) 0.01
Coronary artery disease 1.85 (1.23–2.77) 0.003
Congestive heart failure 1.47 (0.97–2.21) 0.07
Hemoglobin (per 1-g/dl increase) 0.82 (0.72–0.94) 0.006
CI, confidence interval; HR, hazard ratio.
Model also adjusted for age; gender; race; intradialytic weight loss; diabetes,
presence of left ventricular hypertrophy, serum calcium, serum phosphorus,
hypoalbuminemia, nitrates, and treatment group. Variables removed from the final
model with P-value of40.15 included history of arrhythmia, hypertension, Hispanic
ethnicity, peripheral vascular disease, serum creatinine, erythropoietin stimulating
agent use, and the use of angiotensin-converting enzyme inhibitor, b-blocker, and
calcium channel blocker.
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pulse pressure with hemodialysis is more strongly predictive
of clinical outcomes than elevated post-dialysis pulse
pressure. This may be due to the known inaccuracies of
dialysis-unit-obtained blood pressure measurements in
estimating interdialytic hemodynamic burden,13 and blood
pressure changes during hemodialysis may be better reflec-
tions of a patients underlying arterial compliance and
cardiovascular risk. Alternatively, reduction in pulse pressure
during hemodialysis may represent a patient with better
overall blood pressure control and lower risk for subsequent
cardiovascular outcomes.
While this study is the first to suggest a positive
association between decrease in pulse pressure during
hemodialysis and short-term outcomes in hemodialysis
subjects, studies in the general population have shown that
reductions in pulse pressure (by decreasing systolic blood
pressure more than diastolic blood pressure) with therapeutic
interventions are associated with improved cardiovascular
outcomes.6 In a meta-analysis of 10 randomized controlled
trials of blood pressure reduction in hypertensive patients,
greater reductions in systolic blood pressure relative to
diastolic blood pressure (across all age groups) were
associated with decreased fatal and non-fatal cardiovascular
events.6 Although there are few available randomized
controlled trials of antihypertensive therapy in hemodialysis
patients,14–20 the use of certain agents (such as inhibitors of
the renin–angiotensin system or carvedilol) has been
demonstrated to improve cardiovascular outcomes. Further,
longer slower dialysis modalities, which control blood
pressure better than conventional hemodialysis, have been
demonstrated to improve left ventricular hypertrophy.21,22
Whether therapeutic interventions (such as certain medications
Table 5 | Rates of treatment-related complications or use of specific therapies during hemodialysis occurring in the 6-month
follow-up among patients categorized by baseline pulse pressure changes during hemodialysis
Complication or therapy
DPulse pressure
(o13.8mmHg,
n¼ 111)
DPulse pressure
(X13.8mmHg,
o5.4mmHg, n¼ 108)
DPulse pressure
(X5.4mmHg,
o2.6mmHg, n¼ 108)
DPulse pressure
(X2.6mmHg,
n¼ 111) P-value
Intradialytic hypotension 0.087 (0.13) 0.069 (0.14) 0.049 (0.10) 0.058 (0.14) 0.008
Treated or symptomatic intradialytic
hypotension
0.047 (0.07) 0.049 (0.12) 0.029 (0.05) 0.027 (0.05) 0.006
Intradialytic use of medication 0.11 (0.12) 0.10 (0.10) 0.084 (0.08) 0.069 (0.07) 0.06
Dialysis session complicated by
cramping, dizziness, or nausea/
vomiting
0.12 (0.13) 0.12 (0.13) 0.10 (0.09) 0.11 (0.11) 0.8
Administration of hypertonic saline or
use of sodium modeling
0.19 (0.34) 0.23 (0.37) 0.15 (0.32) 0.095 (0.27) 0.08
Use of cool dialysate (temp.o361C) 0.019 (0.09) 0.009 (0.03) 0.033 (0.10) 0.022 (0.05) 0.009
Rates are defined as the number of treatments during which the event occurred divided by the total number of dialysis sessions. Event rates are reported as means (s.d.);
comparisons of events were performed with the non-parametric Kruskal–Wallis test.
10
5
0
–5
–10
–15
–20
–25
Baseline Month 1 Month 2 Month 3 Month 4 Month 5 Month 6
–11.2
–7.2
–3.7
0.5
–11.6
–6.5
–2.8
0.41.2
–1.9
–6.6
–11.1–11.6
–6.4
–2
0.93
–11.1
–7.4
–2.7
2.25.4
–3
–9
–17.5–20.5
–9.9
–1.6
8Quartile 4
Quartile 3
Quartile 2
Quartile 1
Ch
an
ge
 in
 p
ul
se
 p
re
ss
ur
e 
(m
m 
Hg
)
pr
e-
to
 p
os
td
ia
lys
is
Figure 3 |Monthly average change in pulse pressure during dialysis across quartiles of subjects categorized by baseline pulse
pressure change during hemodialysis.
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or changes in dialysis procedure) targeted specifically toward
lowering pulse pressure can improve cardiovascular outcomes
in dialysis patients remains to be determined.
While decrease in pulse pressure with hemodialysis was
associated with improved outcomes in this study, the
underlying mechanisms behind individual blood pressure
responses to ultrafiltration and hemodialysis remain
unknown. Prior investigations have identified roughly half
of hemodialysis patients exhibit a fall in systolic blood
pressure during hemodialysis23 and that this relationship is
short-lived with a rise in systolic blood pressure over
the subsequent 12–24 h.24,25 Greater reductions in blood
pressure during hemodialysis have been postulated to be
mediated by greater decreases in the renin–angiotensin
system and/or decreased sympathetic nervous system
activity in response to decreases in blood volume.2 Alter-
natively, greater reductions in blood pressure with hemodia-
lysis may be due to higher fluid or sodium solute removal in
these individuals; however, 2 prior studies noted that
individual blood pressure responses to hemodialysis are not
related to blood volume changes or volume overload.26,27
Other potential etiologies for differential individual blood
pressure responses to hemodialysis include timing of blood
pressure medications, decreased removal of blood pressure
medications with hemodialysis, different dialysate prescrip-
tions, differing doses of erythropoietin stimulating agents, or
some other unknown factor. While it is likely that all or some
of these factors contribute to individual blood pressure
responses to hemodialysis, in our investigation, subjects with
greater reductions in pulse pressure trended toward greater
fluid removal with hemodialysis and we found no difference
in class of antihypertensive medication.
Interestingly, we identified that subjects with the greatest
reduction in pulse pressure with hemodialysis exhibited
higher dry weights. One prior investigation, analyzing the
relationship between blood pressure and body mass index in
hemodialysis patients, also noted that patients with higher
body mass index exhibited lower post-dialysis systolic blood
pressure compared to under-weight patients.28 The reasons
for this are unclear but possible mechanisms include under-
dialysis in underweight individuals, higher relative volume
shifts triggering excess sympathetic response in lower weight
patients, or alternatively an excess presence of proinflamma-
tory cytokines in underweight and malnourished patients
that may alter endothelial response to hemodialysis resulting
in excess endothelin-1 and vasoconstriction. Under-dialysis
in lower weight patients is unlikely as these patients tend to
receive greater doses of dialysis relative to their body weight
compared to overweight patients.29 Greater volume shifts
relative to body weight resulting in excess sympathetic tone is
possible, but in this study subjects with the greatest decrease
in pulse pressure with hemodialysis also had the highest
percent fluid removal with dialysis. Finally, higher body mass
index has been associated with better nutritional status and
better clinical outcomes in dialysis patients,30–33 thus the
possibility of an abnormal inflammatory response during
hemodialysis and resultant vasoconstriction in underweight
individuals is possible.
This study also noted higher serum calcium among
subjects with greater reductions in pulse pressure during
hemodialysis. Prior investigations have identified higher
serum calcium to be associated with decreased arterial
compliance and increased pulse pressure.34 It is also well
established in hemodialysis patients that an acute rise in
serum calcium with the use of higher calcium dialysate
concentrations increases cardiac contractility, cardiac output,
and can improve hemodynamic instability during hemodia-
lysis.35–38 If one considers dialysate calcium concentration to
be a major determinant of serum calcium level, then one
would expect a lower calcium level among subjects with
greater reductions in pulse pressure during hemodialysis,
which we did not identify. However, considering numerous
other factors contribute to serum calcium levels (such as
calcium containing binders and vitamin D administration) in
hemodialysis patients and we lack information on dialysate
calcium, it is uncertain what influence calcium dialysate
concentrations had on individual blood pressure responses to
hemodialysis in this study.
There are several limitations to the findings of this study.
First, given the observational nature of the present study, we
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Figure 4 |Adjusted* hazard ratio for hospitalization or
death associated with decrease in pulse pressure during
hemodialysis (per 10mmHg) among the following four strata
of pre-dialysis systolic blood pressure: (1) Pre-dialysis systolic
blood pressure o120mmHg (HR 1.39, CI 0.72–2.76, per
10-mmHg decrease in pulse pressure with hemodialysis).
(2) Pre-dialysis systolic blood pressure 120–139mmHg (HR 0.78,
CI 0.54–1.13, per 10-mmHg decrease in pulse pressure with
hemodialysis). (3) Pre-dialysis systolic blood pressure
140–159mmHg (HR 0.76, CI 0.60–0.97, per 10-mmHg decrease in
pulse pressure with hemodialysis). (4) Pre-dialysis systolic blood
pressure X160mmHg (HR 0.79, CI 0.59–1.06, per 10-mmHg
decrease in pulse pressure with hemodialysis). *Each model is
adjusted for age, race, gender, dry weight, intradialytic weight
loss, tobacco use, pre-dialysis systolic blood pressure, diabetes,
cerebrovascular disease, coronary artery disease, congestive
heart failure, presence of left ventricular hypertrophy,
hypoalbuminemia, serum calcium, phosphorus, hemoglobin,
nitrate, and treatment arm. CI, confidence interval; HD,
hemodialysis; HR, hazard ratio; PP, pulse pressure; SBP, systolic
blood pressure.
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cannot make any conclusions regarding cause and effect.
Whether pulse pressure reduction with hemodialysis is merely
a marker of underlying improved vascular compliance or a
marker of better overall blood pressure control remains to be
determined. Second, the blood pressure parameters used for
this analysis were averaged from 2 weeks of blood pressure
measurements; while prior analyses have suggested home
blood pressure recordings to be better estimates of ambula-
tory blood pressure,39 a recent study identified median
hemodialysis unit blood pressure to correlate with ambulatory
blood pressure40 suggesting a pre- to post-dialysis change in
pulse pressure may be a useful correlate of overall hemo-
dynamic burden. This study also lacked information on
calcium and bicarbonate dialysate concentrations, thus limit-
ing our ability to determine whether these parameters
contributed mechanistically to changes in pulse pressure with
dialysis. Finally, the cohort used for this analysis was part of a
randomized controlled trial; given the known volunteer bias,
which likely resulted in a healthier cohort with lower
mortality, these findings may not be applicable to the wider
range of prevalent end-stage renal disease patients included in
the United States Renal Data System.
In conclusion, a greater decrease in pulse pressure during
hemodialysis was associated with improved short-term
clinical outcomes, including hospitalization and death. The
beneficial association between decrease in pulse pressure
during hemodialysis and improved outcomes was not
modified by either high or low pre-dialysis or post-dialysis
pulse pressure, and was most pronounced among
subjects who exhibited pre-dialysis systolic blood pressure
X120mmHg. Further research into the underlying etiology
of individual blood pressure responses to hemodialysis is
needed to determine whether this risk factor is merely a
marker of underlying vascular disease or overall blood
pressure burden, and whether blood pressure responses to
hemodialysis are modifiable.
MATERIALS AND METHODS
Subject population
Subjects enrolled in the Crit Line Intradialytic Monitoring
Benefit Study (CLIMB) were included in this analysis. The methods
and results of the original CLIMB study have been reported
previously.41 In summary, entry criteria to CLIMB included age
between 18–85 years and thrice weekly in-center hemodialysis for
42 months. Patients were excluded if they had any of the following:
blood pressure immeasurable by standard techniques, active
gastrointestinal bleed, severe malnutrition (albumin o2.6 g/dl),
active hematologic disease, planned move or planned living donor
renal transplant, malignancy requiring chemotherapy, and inability
to provide informed consent. The Institutional Review Board (IRB)
at each of the six participating centers approved the original study
protocol and the Duke University IRB approved this analysis.
Study measurements and definitions
In the CLIMB study, hemodialysis subjects were observed for
2 weeks and then randomized to 6 months of intradialytic blood
volume monitoring using Crit-Line* (Hema Metrics Inc. (*formerly
In-Line Diagnostics), Kaysville, UT, USA) or conventional clinical
strategies. Following randomization, subjects were followed for 6
months and the primary end point was non-access-related
hospitalization rates. For this analysis, the primary outcome is a
combined end point of non-access-related hospitalization or death.
At baseline, the following parameters were collected and included
in this analysis: demographics (race, age, and sex); target dry weight;
intradialytic weight loss; dialysis vintage; tobacco use (defined as
current or quit within last 10 years); treatment center; and past
medical history including history of diabetes mellitus, diabetes as
cause of end-stage renal disease hypertension, peripheral vascular
disease, coronary artery disease (defined as history of myocardial
infarction, coronary artery bypass graft, or percutaneous coronary
intervention), congestive heart failure (defined as a history of
congestive heart disease or left ventricular dysfunction), cerebro-
vascular disease (history of transient ischemic attack or stroke),
arrhythmia (cardiac arrest, atrial fibrillation/flutter, atrial/ventricu-
lar tachycardia, or ventricular fibrillation), antihypertensive medica-
tion class, and routine laboratory data.
Baseline blood pressure used for this analysis was averaged from
six hemodialysis sessions over 2 weeks during enrollment. Blood
pressure parameters were measured by trained nurses using
automated devices after the subject was at rest for 5min. For this
analysis, pulse pressure was defined as: systolicdiastolic blood
pressure, and Dpulse pressure was defined as: post-dialysis pulse
pressurepre-dialysis pulse pressure.
During the course of the follow-up, data from each individual
dialysis sessions were recorded thrice weekly. The rate of occurrence
of the following events and treatments were available for analysis:
intradialytic hypotension (defined as a lowest intradialytic systolic
blood pressure p85mmHg); treated or symptomatic intradialytic
hypotension (defined as lowest intradialytic systolic blood pressure
p85mmHg and treatment was given or the patient developed
symptoms); use of intradialytic medications; subject complaints of
symptoms during dialysis, including cramping, dizziness, nausea, or
vomiting; use of sodium modeling or administration of hypertonic
saline; and use of cool dialysate (temperature o361C).
Primary end point
The primary end point for this analysis was time to first non-access-
related hospitalization or death.
Statistical analysis
Four hundred and thirty-eight of the original 443 subjects initially
enrolled in the CLIMB study were included in this analysis. Subjects
were excluded if they failed to follow-up after enrollment (n¼ 1) or
if they were missing baseline pre- or post-dialysis blood pressure
measurements (n¼ 4).
For descriptive purposes, subjects were grouped into quartiles of
pulse pressure changes during dialysis. Categorical variables are
presented as percentages and compared with w2-tests. Continuous
variables are reported as means (±s.d.) unless otherwise noted.
One-way analysis of variance was used to compare normally
distributed continuous variables; otherwise non-parametric
Kruskal–Wallis test was used. Categorical variables with missing
data were assumed to be absent (B1%). For continuous variables
with missing data (only creatinine and hemoglobin, o5%), the
variable was replaced with the overall mean for the final analyses.
Final models were analyzed with and without imputation and the
results are similar to those presented.
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In unadjusted analysis stratified by original randomization,
Kaplan–Meier curves were used to separately describe the relation-
ship between pre-dialysis pulse pressure, post-dialysis pulse
pressure, Dpulse pressure, and the primary end point of time to
first non-access-related hospitalization or death. Cox proportional
hazards assumptions were tested by formal and graphical
methods. Continuous variables with non-linear associations with
the primary end point were transformed into categorical variables.
In adjusted analysis, Cox proportional hazards models were
used to determine the relationship between Dpulse pressure (as a
continuous variable) and the primary end point while controlling
for demographics, comorbid conditions, laboratory variables,
and blood pressure medications. Demographic variables and
variables, which have been demonstrated to be associated with
adverse outcomes (age, gender, race, diabetes, treatment group, and
albumin), were included in all models. Variables, which were
significantly different between quartiles of patients categorized by
pulse pressure changes with hemodialysis, were also included in
all models. Other variables, which were not associated with
the primary end point (P40.15), were removed from the final
model by backward selection. Additional adjusted models were
created, which analyzed the relationship between pre-dialysis pulse
pressure, post-dialysis pulse pressure, and Dpulse pressure (tested
individually and in combination), and the primary composite end
point. Box plots were created to graphically display the adjusted
HRs and 95% CIs associated with the different blood pressure
parameters. Adjusted analyses were also performed with Dpulse
pressure as a time-varying covariate in which monthly average
Dpulse pressure was analyzed in association with the subsequent
primary end point.
Sensitivity analyses were performed by adding pre-dialysis
systolic blood pressure to the final model to determine if this
modified the relationship between Dpulse pressure and the primary
end point. Separate stratified analyses among four strata of pre-
dialysis systolic blood pressure (o120, 120–139, 140–159,
and 4160mmHg) were performed to determine whether the
relationship between Dpulse pressure and the primary end point
differed with the level of pre-dialysis systolic blood pressure. Separate
models also tested whether interactions were present between Dpulse
pressure and intradialytic weight loss and antihypertensive agent class.
All statistical analyses were performed using SAS Eguide (version
9.2; SAS Institute, Cary, NC, USA).
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